Single center single arm clinical prospective study of neoantigen reactive T cells (NRTs) combined with PD-1 inhibitor in the treatment of Chinese patients with advanced refractory solid tumors

Status: Suspended

Phase of Trial: Phase I/II

Latest Information Update: 05 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Camrelizumab (Primary) ; Neoantigens reactive T cell therapy (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
Indications Solid tumours
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms NRT-01

01 Aug 2017 Status changed from recruiting to suspended, according to an Incyte Corporation media release.
02 Jun 2017 Status changed from not yet recruiting to recruiting.
04 May 2017 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com